Induction of promyelocytic leukemia zinc finger protein by miR-200c-3p restores sensitivity to anti-androgen therapy in androgen-refractory prostate cancer and inhibits the cancer progression via down-regulation of integrin α3β4
Cellular Oncology · 2023
DOI: 10.1007/s13402-023-00803-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2023. Verfasst von Sadan Dahal und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Yeungnam University, 280 Daehak-Ro, Gyeongsan, 38541, Republic of Korea. Hauptthemen laut MEDLINE: Prostatic Neoplasms, MicroRNAs. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Yeungnam University, 280 Daehak-Ro, Gyeongsan, 38541, Republic of Korea.
- College of Pharmacy, Yeungnam University, 280 Daehak-Ro, Gyeongsan, 38541, Republic of Korea. jakim@yu.ac.kr.
Zitieren
APA
Dahal, S., Chaudhary, P., & Kim, J. A. (2023). Induction of promyelocytic leukemia zinc finger protein by miR-200c-3p restores sensitivity to anti-androgen therapy in androgen-refractory prostate cancer and inhibits the cancer progression via down-regulation of integrin α3β4. Cellular Oncology. https://doi.org/10.1007/s13402-023-00803-y
Vancouver
Dahal S, Chaudhary P, Kim JA. Induction of promyelocytic leukemia zinc finger protein by miR-200c-3p restores sensitivity to anti-androgen therapy in androgen-refractory prostate cancer and inhibits the cancer progression via down-regulation of integrin α3β4. Cellular Oncology. 2023. doi:10.1007/s13402-023-00803-y
BibTeX
@article{Dahal2023,
author = {Dahal, Sadan and Chaudhary, Prakash and Kim, Jung-Ae},
title = {Induction of promyelocytic leukemia zinc finger protein by miR-200c-3p restores sensitivity to anti-androgen therapy in androgen-refractory prostate cancer and inhibits the cancer progression via down-regulation of integrin α3β4},
journal = {Cellular Oncology},
year = {2023},
doi = {10.1007/s13402-023-00803-y}
}
EUVIMED